SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about innovent announces first participant dosed in a phase 1 clinical trial of ibi3011 a recombinant anti human interleukin 1 receptor accessory protein monoclonal antibody was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody )
Also on site :
- Ann Godoff, Penguin Press Founder and Editor, Dies at 76
- Starmer urges voters to reject ‘toxic’ politics in last ditch plea to win crucial Gorton and Denton by-election
- WI vs SA Dream11 Prediction Today Match, Dream11 Team Today, Fantasy Cricket Tips, Playing XI, Pitch Report, Injury Update- ICC T20 World Cup 2026, Match 47